Viridium Pacific Group Ltd. (TSXV:VIR) signed a letter of intent to acquire EFX Laboratories Inc. for CAD 25.1 million on December 12, 2018. Viridium Pacific Group signed an agreement acquire EFX Laboratories on January 7, 2019. Viridium will acquire all of the issued and outstanding class A voting shares of EFX by the issuance of common shares in the capital of Viridium, which will be issued on the basis of one Viridium share for every 2.57 EFX shares. On completion of transaction, it is anticipated that the current holders of EFX shares will hold approximately 48.2 million Viridium shares, representing approximately 49.41% of the outstanding Viridium shares and the current holders of Viridium shares will hold 49.3 million Viridium shares, representing approximately 50.59% of the outstanding Viridium shares. In the event of the termination of the agreement, EFX and Viridium shall pay an amount equal to CAD 0.5 million. Upon completion of the transaction, Viridium’s Board of Directors will be comprised of five existing Viridium Directors and two existing EFX Directors. Viridium’s management team will remain unchanged and be comprised of Jay Garnett, President and Chief Executive Officer and Jarrett Malnarick, Senior Vice President and Chief Operating Officer. The transaction is subject to the satisfaction of a number of conditions, including but not limited to, TSXV granted conditional approval, EFX shareholder approval, information circular and other documentation required in connection with the EFX meeting shall have been mailed on or before January 18, 2019, and all material governmental authority approvals and third party approvals. Viridium shareholder approval will not be required. The transaction has been approved unanimously by the Board of Directors of EFX and Viridium. The transaction is expected to close in February 2019. Mathew August of Animus Capital Partners Inc. acted as financial advisor to Viridium. Scott R. Cochlan of Torys LLP and Steven Lukas of Harper Grey LLP acted as legal advisors for Viridium. Sarah Gingrich of Fasken Martineau DuMoulin LLP acted as legal advisor for EFX.